MSLN and neoplasm: Notably, the use of 4Gy x 1 fraction prior anti-mesothelin CAR-T cell therapy led to the most effective tumor control (Figure 3C) and a 100% survival rate (Figure 3F1) at day 75 [i.e., size of tumors ~ 350 mm3 after 4Gy x 1 fraction + CAR-T vs. ~ 1150 mm3 after CAR-T only (p<0.005) or ~1650 mm3 after 4Gy x 1 fraction only (p<0.0003)].